September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Treatment of retinitis pigmentosa by Lycium barbarum
Author Affiliations & Notes
  • Henry Ho-lung Chan
    Laboratory of Experimental Optometry (Neuroscience), School of Optometry, The Hong Kong Polytechnic University, Hong Kong, Hong Kong
  • Christie Hang I Lam
    Laboratory of Experimental Optometry (Neuroscience), School of Optometry, The Hong Kong Polytechnic University, Hong Kong, Hong Kong
  • Kwok-Fai So
    Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
  • Raymond Chuen-chung Chang
    Laboratory of Neurodegenerative Diseases, School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
  • Jimmy Shiu Ming Lai
    Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong
  • Chi-wai Do
    Laboratory of Experimental Optometry (Neuroscience), School of Optometry, The Hong Kong Polytechnic University, Hong Kong, Hong Kong
  • Iris FF Benzie
    Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, Hong Kong
  • Serena ZC Li
    Laboratory of Experimental Optometry (Neuroscience), School of Optometry, The Hong Kong Polytechnic University, Hong Kong, Hong Kong
  • Kaiyip Choi
    Laboratory of Experimental Optometry (Neuroscience), School of Optometry, The Hong Kong Polytechnic University, Hong Kong, Hong Kong
  • Man Pan Chin
    Laboratory of Experimental Optometry (Neuroscience), School of Optometry, The Hong Kong Polytechnic University, Hong Kong, Hong Kong
  • Wing Yan Yu
    Laboratory of Experimental Optometry (Neuroscience), School of Optometry, The Hong Kong Polytechnic University, Hong Kong, Hong Kong
  • Footnotes
    Commercial Relationships   Henry Chan, None; Christie Lam, None; Kwok-Fai So, None; Raymond Chang, None; Jimmy Lai, None; Chi-wai Do, None; Iris Benzie, None; Serena Li, None; Kaiyip Choi, None; Man Pan Chin, None; Wing Yan Yu, None
  • Footnotes
    Support  Health and Medical Research Fund (01121876), General Research Funds (PolyU5605/13M), PolyU Internal Grants (G-YBBS, G-YBGS, Z-0GF, G-UB83, G-YK88)
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 135. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Henry Ho-lung Chan, Christie Hang I Lam, Kwok-Fai So, Raymond Chuen-chung Chang, Jimmy Shiu Ming Lai, Chi-wai Do, Iris FF Benzie, Serena ZC Li, Kaiyip Choi, Man Pan Chin, Wing Yan Yu; Treatment of retinitis pigmentosa by Lycium barbarum. Invest. Ophthalmol. Vis. Sci. 2016;57(12):135.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : To study the immediate effect of Lycium barbarum (LB) treatment on retinal functions, especially the cone function, in patients with retinitis pigmentosa (RP).

Methods : The study is a double-masked randomized clinical trial. RP subjects were recruited with eye examination including ETDRS Visual Acuity, Humphrey Field Analysis and Multifocal Electroretinogram. The RP subjects were randomly allocated to either LB or placebo groups with daily treatment (10g/day) for 12 months and had follow up in every 6 months.

Results : It is the report after the first 6 months of intervention. There were 23 subjects in LB group (49.8±13.3yr) and 12 in placebo group (46.5±10.2yr); p=0.43). The compliance rates for LB and placebo groups were 89±8.2% and 85±11.1% respectively (p=0.30).
The changes of 90% contrast VA for LB and placebo groups were -0.01±0.05 and 0.07±0.12 respectively (p=0.09). The changes of 10% contrast VA for LB and placebo groups were -0.05±0.08 and 0.06±0.07 respectively which were significantly different (p=0.047). The changes of mean defect from HFA 30-2 full-threshold for LB and placebo groups were -0.33±0.80dB and -0.06±0.63dB respectively (p=0.50). The changes of mean defect from HFA 10-2 full-threshold for LB and placebo groups were -0.13±1.10dB and -1.40±1.25dB respectively which were significantly different (p=0.04).
The amplitude changes of direct component (DC) from global flash mfERG for LB and placebo groups were: -2.44±4.25nV/°2 (Central, C); -0.14±1.13nV/°2 (Paracentral, P) and 2.01±8.52nV/°2 (C); 0.03±0.83nV/°2 (P) respectively. The amplitude changes of induced component (IC) from mfERG for LB and placebo groups were -5.28±12.2nV/°2 (C); -0.23±1.30nV/°2 (P) and -0.73±4.71nV/°2 (C); -0.33±0.58nV/°2 (P) respectively. The implicit time changes of DC for LB and placebo groups were: 0.73±3.07msec (C); 0.64±4.71msec (P) and 1.55±4.28 msec (C); -0.35±2.51msec (P) respectively. The implicit time changes of IC for LB and placebo groups were: 1.41±2.52msec (C); 1.21±5.42msec (P) and 0.42±4.81msec (C); -0.52±4.82msec (P) respectively. No significance were observed in all mfERG parameters (p>0.05).

Conclusions : Our results confirm that the 6 months LB treatment for RP patients had marginal significant improvement in low-contrast VA and central visual sensitivity. The neuroprotective effect of LB is believed to delay or minimize the deterioration of central visual function in RP.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×